T790M陽性非小細胞肺がんの中枢神経系転移(CNS)へのオシメルチニブの効果:第Ⅲ相ランダム化比較試験AURA3データの検証【J Clin Oncol】

CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)

J Clin Oncol 2018年7月30日オンライン版

Purpose In patients with epidermal growth factor receptor ( EGFR) mutation-positive advanced non-small-cell lung cancer (NSCLC), there is an unmet need for EGFR-tyrosine kinase inhibitors with improved CNS penetration and activity against CNS metastases, either at initial diagnosis or time of progression.





Leave a comment

Your email address will not be published.